Breaking News Instant updates and real-time market news.

RHHBY

Roche

$30.22

-0.28 (-0.92%)

05:32
12/11/17
12/11
05:32
12/11/17
05:32

Genentech says Phase III IMmotion151 Study rhowed reduced risk of worsening

Genentech, a member of the Roche Group, announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival, or PFS, and demonstrated that the combination of TECENTRIQ and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death, or PFS, in people whose disease expressed the PD-L1 protein compared with sunitinib for the first-line treatment of people who have advanced or metastatic renal cell carcinoma, or mRCC. Observations of a pre-specified subgroup analysis of the TECENTRIQ and Avastin combination indicated that, in people whose disease expressed PD-L1, a numerical difference favoring TECENTRIQ was seen across all patient risk factor groups compared to sunitinib; however, due to the study design these data could not be assessed for statistical significance and are descriptive only. Assessment of secondary endpoints is ongoing. Safety for the TECENTRIQ and Avastin combination appeared consistent with the known safety profile of the individual medicines and what was previously reported in the Phase II IMmotion150 study. No new safety signals were identified with the combination. Results will be presented at an upcoming oncology conference in 2018. Top-line results from the co-primary endpoint of overall survival, or OS, are not mature.

  • 23

    Dec

  • 23

    Feb

RHHBY Roche
$30.22

-0.28 (-0.92%)

11/22/17
COWN
11/22/17
NO CHANGE
Target $105
COWN
Outperform
Impressive Venclexta abstract positive for AbbVie, says Cowen
Cowen analyst Steven Scala said a late breaking ASH abstract showed impressive data for AbbVie's Venclexta drug used in chronic lymphocytic leukemia. The analyst has modeled $2.6N in sales in 2024 and company guidance suggests sales could reach $6B in 2025. Scala reiterated his Outperform rating and $105 price target on AbbVie shares.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Overweight
Roche to outperform on 'very strong' lung cancer data, says JPMorgan
JPMorgan analyst Richard Vosser says Roche reported "very strong" detailed progression free survival data from its IMPower150 lung cancer study. At the conference later today, the analyst expects to see strong interim overall survival data. He expects the shares to outperform by 1%-2% following this morning's data. Vosser has an Overweight rating on Roche.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.

TODAY'S FREE FLY STORIES

TXT

Textron

$66.80

0.13 (0.19%)

09:49
07/17/18
07/17
09:49
07/17/18
09:49
Technical Analysis
Technical Earnings Preview: Textron near highs before news »

The stock is in a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GS

Goldman Sachs

$230.50

-0.51 (-0.22%)

09:48
07/17/18
07/17
09:48
07/17/18
09:48
Hot Stocks
Goldman Sachs CFO says investment banking backlog reached record in Q2 »

Goldman Sachs CFO Marty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:48
07/17/18
07/17
09:48
07/17/18
09:48
Conference/Events
Cowen Internet & new media analyst to hold an analyst/industry conference call »

Internet & New Media…

09:47
07/17/18
07/17
09:47
07/17/18
09:47
General news
Netflix slide leading Nasdaq to struggle at open »

Stock futures fell during…

SERV

ServiceMaster

$61.85

(0.00%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
ServiceMaster falls -5.7% »

ServiceMaster is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

HZN

Horizon Global

$6.89

(0.00%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Horizon Global falls -6.6% »

Horizon Global is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMC

Omnicom

$72.81

-5.31 (-6.80%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Omnicom falls -6.9% »

Omnicom is down -6.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 09

    Aug

IGT

International Game

$25.17

0.78 (3.20%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
International Game rises 3.5% »

International Game is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

GOL

Gol Linhas

$6.66

0.27 (4.23%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Gol Linhas rises 3.8% »

Gol Linhas is up 3.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPI

Farmland Partners

$6.54

0.445 (7.30%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Farmland Partners rises 7.0% »

Farmland Partners is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATM

Cardtronics

$26.60

(0.00%)

09:46
07/17/18
07/17
09:46
07/17/18
09:46
Recommendations
Cardtronics analyst commentary  »

Cardtronics immediate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Housing Market Index to be reported at 10:00 »

July Housing Market Index…

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Breaking General news story  »

Federal Reserve Chairman…

CMCSA

Comcast

$34.98

(0.00%)

, CMCSK

Comcast

$0.00

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Periodicals
NBCU relaunches Craftsy as subscription-video service Bluprint, Variety reports »

NBCUniversal Cable…

CMCSA

Comcast

$34.98

(0.00%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Hot Stocks
Johnson & Johnson says 'disappointed' in Spine & Knee medical sales results »

Says Spine still an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

BA

Boeing

$356.01

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Hot Stocks
Boeing, Xiamen Airlines announce optimized maintenance program deal »

Boeing and Xiamen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SNA

Snap-On

$163.93

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Recommendations
Snap-On analyst commentary  »

Snap-On checks point to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 16

    Aug

VEON

Veon

$3.05

(0.00%)

, HFC

HollyFrontier

$68.91

(0.00%)

09:40
07/17/18
07/17
09:40
07/17/18
09:40
Options
Unusually active option classes on open July 17th »

Unusual total active…

VEON

Veon

$3.05

(0.00%)

HFC

HollyFrontier

$68.91

(0.00%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$25.49

(0.00%)

UNH

UnitedHealth

$257.03

(0.00%)

JNJ

Johnson & Johnson

$124.70

(0.00%)

CZR

Caesars

$11.63

(0.00%)

GS

Goldman Sachs

$231.01

(0.00%)

MCD

McDonald's

$158.76

(0.00%)

ATVI

Activision Blizzard

$80.23

(0.00%)

GDX

Market Vector Gold Miners

$21.88

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

09:38
07/17/18
07/17
09:38
07/17/18
09:38
Recommendations
Netflix analyst commentary  »

Netflix Q2 weakness is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$194.01

-2 (-1.02%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Initiation
Wex initiated  »

Wex initiated with a Peer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Periodicals
Lloyd Blankfein writes farewell memo to Goldman Sachs team, NY Times reports »

Goldman Sachs CEO LLoyd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$58.79

1.04 (1.80%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Recommendations
Nevro analyst commentary  »

Nevro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

FLT

FleetCor

$216.11

-4.06 (-1.84%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FleetCor initiated  »

FleetCor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$66.95

-0.06 (-0.09%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
Square initiated  »

Square initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

FIS

FIS

$107.72

-0.45 (-0.42%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FIS initiated  »

FIS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.